Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches Breakthrough demonstrates the potential of 3D multi-omics to revolutionize drug discovery timelines and success rates across various disease areas Cambridge, UK, 24th June 2025: Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D […]

Cambridge, UK, 14 January 2025: Enhanc3D Genomics (‘Enhanced’ or ‘the Company’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery. Based on the Company’s proprietary 3D genomics platform, integrated with extensive multi-omics analysis, the new 3D Multi-omic offerings […]

Key appointment supports company growth and strategic commercial and academic partnerships Cambridge, UK, 06 November 2023: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer. Following a £10 million Series A financing in October 2022, […]

GenLink3DTM provides the first high-resolution mapping of DNA interactions in 3D space, enabling the vast array of non-coding genetic variations to be deciphered into actionable disease biomarkers and treatment targets Funds will be used to rapidly generate deep datasets of novel diagnostic signatures and candidate therapeutic targets across multiple immune-related diseases for internal and external […]

We are developing a technology to unlock the full potential of the 3D organisation of the #humangenome to identify #disease-associated #genetic interactions including those that are causal for disease susceptibility and progression.